• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CTS Corporation Announces Appointment of Amy M. Dodrill to its Board of Directors

    2/8/24 5:30:00 PM ET
    $CTS
    $PRCT
    Electrical Products
    Technology
    Medical/Dental Instruments
    Health Care
    Get the next $CTS alert in real time by email

    LISLE, Ill., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced that Amy M. Dodrill has been appointed to its board of directors, effective February 8, 2024, and will serve as a member of the nominating, governance and sustainability and technology and transactions committees.

    Ms. Dodrill comes to CTS with over 25 years of experience in medical and technology companies and a proven track record of successfully leading and profitably growing global businesses serving key end markets. Ms. Dodrill most recently served as President of Baxter's Global Surgical Solutions and Patient Support Systems segment, a $2 billion business with innovative products focused on advancing connected care and patient outcomes. In that role, Ms. Dodrill successfully integrated two former Hillrom business units into Baxter. Ms. Dodrill is a member of the board of directors of Procept BioRobotics (NASDAQ:PRCT), a commercial stage surgical robotics company, serving on the audit and compensation committees.

    "CTS is pleased to welcome Amy Dodrill to the CTS board.   Her extensive experience in the medical end market and background leading global businesses make her a valuable addition to our already highly experienced and diverse group of directors as CTS continues to focus on growth, end-market diversification, and products that sense, connect and move," said Kieran O'Sullivan, Chairman, President and CEO of CTS.

    About CTS

    CTS (NYSE:CTS) is a leading designer and manufacturer of products that Sense, Connect, and Move. The company manufactures sensors, actuators, and electronic components in North America, Europe, and Asia, and provides engineered products to customers in the aerospace/defense, industrial, medical, and transportation markets. For more information, visit www.ctscorp.com.

    Contact

    Ashish Agrawal

    Vice President and Chief Financial Officer

    CTS Corporation

    4925 Indiana Avenue

    Lisle, IL 60532

    USA

    Telephone: +1 (630) 577-8800

    Email: [email protected]



    Primary Logo

    Get the next $CTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTS
    $PRCT

    CompanyDatePrice TargetRatingAnalyst
    PROCEPT BioRobotics Corporation
    $PRCT
    3/6/2026$30.00Neutral
    Robert W. Baird
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026Outperform → Perform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    2/26/2026$20.00Neutral → Underperform
    BofA Securities
    PROCEPT BioRobotics Corporation
    $PRCT
    12/12/2025$62.00Buy
    UBS
    PROCEPT BioRobotics Corporation
    $PRCT
    12/8/2025$38.00Buy → Neutral
    BofA Securities
    PROCEPT BioRobotics Corporation
    $PRCT
    9/2/2025$60.00Perform → Outperform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    7/9/2025$70.00Overweight
    Stephens
    PROCEPT BioRobotics Corporation
    $PRCT
    7/7/2025Perform
    Oppenheimer
    More analyst ratings

    $CTS
    $PRCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CLO, CORP. SEC. Nouri Alaleh sold $83,197 worth of shares (3,243 units at $25.65), decreasing direct ownership by 3% to 111,021 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/12/26 4:02:33 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 7:19:42 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    President, CEO Wood Larry L was granted 127,783 shares, increasing direct ownership by 69% to 313,378 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 5:45:06 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $CTS
    $PRCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy

    SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT), today announced the international expansion of the HYDROS Robotic System, the company's next-generation platform for delivering Aquablation therapy to treat benign prostatic hyperplasia (BPH). HYDROS is the first AI-enabled robotic platform designed specifically for the treatment of BPH with Aquablation therapy. Leveraging AI-interpreted, real-time ultrasound imaging and advanced image-guided treatment planning, the system enables surgeons to deliver personalized, anatomy-specific therapy with robotic precision and reproducibility. The platform is designed to support scalable adoption across care setti

    3/12/26 9:00:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth

    Company outlines path to leadership in BPH, including near-term focus on procedure growth through patient-centric solutions and increased organizational disciplineStrong revenue outlook, procedure growth, expanding margins, and path to profitabilityLonger-term growth drivers include market expansion and expanded application into prostate cancer NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today hosted its 2026 Investor Day event in New York to detail the Company's market opportunity, long-term strategy and growth goa

    2/26/26 7:55:00 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commer

    2/25/26 4:02:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $CTS
    $PRCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on PROCEPT BioRobotics with a new price target

    Robert W. Baird initiated coverage of PROCEPT BioRobotics with a rating of Neutral and set a new price target of $30.00

    3/6/26 8:35:41 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by Oppenheimer

    Oppenheimer downgraded PROCEPT BioRobotics from Outperform to Perform

    2/26/26 7:23:22 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics downgraded by BofA Securities with a new price target

    BofA Securities downgraded PROCEPT BioRobotics from Neutral to Underperform and set a new price target of $20.00

    2/26/26 7:11:50 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $CTS
    $PRCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 7:19:42 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $CTS
    $PRCT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by PROCEPT BioRobotics Corporation

    SCHEDULE 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    3/6/26 10:05:20 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by PROCEPT BioRobotics Corporation

    S-8 - PROCEPT BioRobotics Corp (0001588978) (Filer)

    2/26/26 4:51:15 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by PROCEPT BioRobotics Corporation

    10-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

    2/26/26 4:04:58 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $CTS
    $PRCT
    Leadership Updates

    Live Leadership Updates

    View All

    CTS Corporation Appoints Pratik Trivedi as Chief Operating Officer

    LISLE, Ill. , Nov. 26, 2025 (GLOBE NEWSWIRE) -- CTS Corporation today announced the appointment of Pratik Trivedi to Chief Operating Officer (COO), effective December 5. Mr. Trivedi, who is Senior Vice President at CTS, brings deep industry experience from prior leadership positions at Eaton Corporation and Cummins Inc. "I am very pleased that Pratik will assume the role of COO. His experience, focus and leadership will be important to executing our growth strategy," commented Kieran O'Sullivan, Chairman and CEO of CTS.  "Pratik has demonstrated an ability to lead and deliver results since joining CTS and I am confident that he will be highly effective as COO."   About CTS CTS Corporat

    11/26/25 9:15:00 AM ET
    $CTS
    Electrical Products
    Technology

    CTS Corporation Announces Appointment of Kimberly Banks MacKay to its Board of Directors

    LISLE, Ill., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced that Kimberly Banks MacKay has been appointed to its Board of Directors, effective November 5, 2025, and that she will serve as a member of the Nominating, Governance and Sustainability Committee, as well as the Technology and Transactions Committee. Ms. MacKay comes to CTS with over 30 years of experience driving results in multi-national companies serving key end markets. Ms. MacKay currently serves as SVP, General Counsel and Corporate Secretary of West Pharmaceutical Services, Inc. Ms. MacKa

    11/6/25 9:00:00 AM ET
    $CTS
    Electrical Products
    Technology

    CTS Corporation Announces the Appointment of Mark Pacioni as Chief Legal & Administrative Officer and Corporate Secretary

    LISLE, Ill., July 01, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS) today announced that Mark Pacioni has been appointed Chief Legal & Administrative Officer and Corporate Secretary, effective July 1, 2025. Prior to joining CTS, Mr. Pacioni served as Chief Legal Officer and Secretary of CareerBuilder, LLC from 2019 to 2024 and its successor company, CareerBuilder + Monster, from 2024 until June 2025. Prior thereto, he held senior legal roles at The Boeing Co., Molex, Inc., and Knowles Corp. In addition to his in-house experience, Mr. Pacioni was in private practice representing public companies on transactions and governance matters and was Special Counsel at the U.S. Securities and

    7/1/25 9:00:00 AM ET
    $CTS
    Electrical Products
    Technology

    $CTS
    $PRCT
    Financials

    Live finance-specific insights

    View All

    PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance

    SAN JOSE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended December 31, 2025. "In the fourth quarter, we delivered our highest procedure volume to date—approximately 12,200—and sold 65 new systems, marking our strongest capital quarter," said Larry Wood, Chief Executive Officer. "At the same time, we took meaningful steps to position the Company for its next phase of growth. To sharpen our focus on delivering durable procedure growth, we realigned our commer

    2/25/26 4:02:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day

    SAN JOSE, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that it has updated the timing of its previously announced fourth quarter 2025 earnings conference call and Investor Day due to significant travel disruptions caused by inclement weather. The Company will report financial results for the fourth quarter of 2025 after market close on Wednesday, February 25, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. The Company also announced it has r

    2/23/26 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    CTS Corporation Declares a Dividend

    LISLE, Ill., Feb. 12, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE:CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on April 24, 2026, to shareholders of record at the close of business on March 27, 2025. About CTS CTS Corporation (NYSE:CTS) is a leading designer and manufacturer of products that Sense, Connect and Move. CTS manufactures sensors, actuators and electronic components in North America, Europe and Asia, and provides engineered products to customers in the aerospace/defense, industrial, medical and transportation markets. For more information, visit www.ctscorp.com. Contact

    2/12/26 3:19:08 PM ET
    $CTS
    Electrical Products
    Technology

    $CTS
    $PRCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by CTS Corporation

    SC 13G/A - CTS CORP (0000026058) (Subject)

    11/14/24 1:28:29 PM ET
    $CTS
    Electrical Products
    Technology

    SEC Form SC 13G filed by CTS Corporation

    SC 13G - CTS CORP (0000026058) (Subject)

    11/14/24 12:28:26 PM ET
    $CTS
    Electrical Products
    Technology